



COPY C

1600

JC16 Rec'd PCT/PTO 20 MAY 2002

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED
WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT
POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:
ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

ON MAY 6, 2002

ATTORNEY FOR APPLICANTS

DATE

COPY OF PAPER
ORIGINALLY FILEDTECH CENTER 1600/2900
JUN 18 2002RECEIVED
JUN 18 2002

Attorney Docket No.: P32286

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Blackler, et al.
Serial No.: 10/019,355
Filed: March 22, 2002
For: THIAZOLIDINEDIONE DERIVATIVE AND ITS USE AS
ANTIDIABETIC

REQUEST FOR CORRECTED FILING RECEIPT


To Assistant Commissioner for Patents

Enclosed herewith is a copy of the Filing Receipt issued by the United States Patent
and Trademark Office with changes noted thereon.


Applicants respectfully request that the United States Patent and Trademark Office
correct the noted errors and issue an amended Filing Receipt.

These errors appear to be on the part of the United States Patent and Trademark
Office since they are not present in the applicant's file copy of the application.

Respectfully submitted,


Yuriy P. Stercho, Ph.D.
Attorney for Applicants
Registration No. 33,797

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5018
Facsimile (610) 270-5090
N:\YPS\RESPONSE\P32286\CorFilRecpt.doc

RECEIVED COPY OF PAPERS
ORIGINALLY FILED

JUN 18 2002

UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.govPage 1 of 2
RECEIVED
JUN 18 2002
TECH CENTER

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/019,355	03/22/2002	1614	1020	P32286	2	9	2

CONFIRMATION NO. 1395

FILING RECEIPT



OC000000007839587

20462
SMITHKLINE BEECHAM CORPORATION
CORPORATE INTELLECTUAL PROPERTY-US, UW2220
P. O. BOX 1539
KING OF PRUSSIA, PA 19406-0939

Date Mailed: 04/11/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Paul David James Blackler, Cadiz, SPAIN;
Robert Gordon Giles, Kent, UNITED KINGDOM;
Michael John Sasse, Kent, UNITED KINGDOM;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/GB00/01521 04/19/2000

Foreign Applications

UNITED KINGDOM 9909041.7 04/20/1999

Projected Publication Date: Not Applicable, filed prior to November 29, 2000

Non-Publication Request: No

Early Publication Request: No

Title

Novel pharmaceutical

Thiazolidinedione Derivative
and its Use As Antidiabetic

Preliminary Class

514

2002 APR 22 A 10:21

RECEIVED
SMITHKLINE

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).